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Psoriatic arthritis (PsA) is an inflammatory arthritis with multiple manifestations:
peripheral/axial arthritis, enthesitis, dactylitis, psoriasis, and nail involvement. From having
an agreed upon classification criteria in 2006, the assessment of PsA has advanced from
uncertainties to development and validation of numerous specific outcome measures.
The Group for Research and Assessment of Psoriasis and Psoriatic arthritis (GRAPPA)
has spearheaded the development of a core domain set and is now working on a core
outcome measurement set to standardize outcome measures for PsA, that will provide
guidance for use of instruments in randomized controlled trials (RCTs) and longitudinal
observational studies (LOS). This article summarizes and updates these work processes
to improve assessment of this multisystem complex rheumatologic disease.
Keywords: psoriatic arthritis, outcome measures, core domains, core instruments, classification criteria

INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. It affects young adults
of working age, with typical age of onset in the 30–50s (1). Destructive changes in bones can develop
early resulting in joint damage and loss of function (2–4). Furthermore, higher inflammatory
burden over time may lead to accelerated atherosclerosis, increased cardiovascular morbidity (5, 6),
and possible early mortality for those with severe disease (7, 8). PsA is a unique disease entity that
is different from other forms of chronic inflammatory arthritis, in terms of clinical manifestations,
pathogenesis, response to treatment, and prognosis (9). Thus, clinicians and rheumatologists need
to be aware of the classification and assessment of PsA to optimize care for these patients. In this
article, we aim to summarize the development of classification criteria and outcome measures in
PsA.

Classification Criteria
An important aspect of studying a “disease entity” is whether one can identify it as sufficiently
homogenous to be distinct from other conditions. Classification criteria serve to ensure that
patients recruited into RCTs have the same “disease,” so that results of these trials can be accurately
interpreted (10, 11), but they are not designed for diagnostic purposes.
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Table 1 summarizes the pros and cons of the various classification
criteria sets for PsA. A comparative study using retrospective
cross sectional and prospective multi-center datasets found
high specificities (>90%), and variable sensitivities (42–98%)
differentiating PsA from RA across these different classification
criteria sets (15). In addition, the performance of different criteria
sets distinguishing PsA from other arthritides has not been tested.
The ClASsification criteria for Psoriatic Arthritis (CASPAR)
study group was established to derive new data driven
classification criteria for PsA (19). The study group subsequently
formed the Group for Research and Assessment in Psoriasis
and Psoriatic Arthritis (GRAPPA) including rheumatologists,

Before 2006, there were no validated case definitions or
universally agreed upon classification criteria for PsA. Most
historical studies used the case descriptive definition proposed
by Moll and Wright (12), which defined PsA as an inflammatory
arthritis in the presence of psoriasis and usually the absence
of rheumatoid factor (RF). Subsequent cohorts from different
centers identified different proportions of PsA patients divided
into asymmetrical oligoarthritis and symmetrical polyarthritis
subgroups (13, 14), possibly because of inclusion of differing
proportions of RF negative rheumatoid arthritis (RA) patients
based on the Moll and Wright case definition (13). Several
classification criteria have subsequently been proposed (15).

TABLE 1 | Operational definition of classification of psoriatic arthritis.
Criteria

Details

Pros and Cons

CASPAR (16)

Inflammatory articular disease (joint, spine, or entheseal)
AND
≥3 points from the following:
• Evidence of psoriasis
- Current psoriasis (scores 2 points) or
- Personal history of psoriasis or
- Family history of psoriasis
• Psoriatic nail dystrophy
• A negative test for rheumatoid factor
• Dactylitis:
- Current dactylitis
- History of dactylitis
• Radiological evidence of juxta-articular new bone formation

Moll and Wright (12)

Arthritis
AND
Psoriasis
AND NOT
Positive Rheumatoid Factor (RF)

ESSG (17)

Synovitis or inflammatory spinal pain
AND
Psoriasis or personal history of psoriasis

Vasey and Espinoza
(18)

Psoriasis or psoriatic nail lesion
AND
Peripheral pattern α or Central patternβ
α: >4 weeks arthritis of DIPJ; or asymmetrical peripheral
arthritis (included sausage digit); absent RF or rheumatoid
nodule; or radiographic changes (Pencil-in-cup deformity,
whittling of terminal phalanges, fluffy periostitis, and bony
ankylosis)
β: >4 weeks Spinal pain and stiffness with the restriction of
motion; or Grade 2 symmetric sacroiliitis, or Grade 3 or 4
unilateral sacroiliitis according to the New York criteria

Pros:
• Developed via international collaborative cohort of PsA experts
• Easy to use
• Good sensitivity and specificity
• Allowing PsA to be classified without psoriasis when other features
are present
• Allowing patients with positive RF to be classified
• Validated in established and early PsA cohorts, and across multiple
ethnicities
• Has gained acceptance and adoption over time
• The most commonly adopted classification in modern randomized
controlled trials (RCTs) and longitudinal observational studies (LOS)
Cons:
• Inflammatory articular disease in joint, spine or enthesis are not
well-defined, could be challenging to use in non-rheumatology
settings
Pros:
• The original diagnostic criteria for PsA
• The simplest and the most frequently used historically
Cons:
• May have used implicit, but undeclared, features for classification,
resulting in later cohorts classifying patients with different features
• Excluded patients with positive RF
• Must have psoriasis to be classified
• The original proposed five subgroups of PsA are not sustained over
time and treatment (Eg polyarthritis vs. oligoarthritis)
Pros:
• Easy to use
• Allows PsA to be classified without current psoriasis
Cons:
• Main purpose of development was to classify Spondyloarthopathies
as a single entity
• Lower sensitivity
Pros:
• Easy to use
• Only describes two patterns of PsA
Cons:
• Must have psoriasis or nail lesions to be classified
• Radiographic changes just classify late disease
• Very few validation studies
• Has not been used in RCTs/LOS

ESSG, European Spondyloarthritis Study Group; CASPAR, ClASsification criteria for Psoriatic Arthritis; PsA, psoriatic arthritis; RCT, randomized controlled trials; LOS, longitudinal
observation studies; RF, rheumatoid factor.
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dermatologists, patients and others, that, with Outcome
Measures in Rheumatology (OMERACT) have pioneered the
work to establish the best outcome measures for PsA. The
CASPAR study group collected data prospectively from 32
centers worldwide, 588 consecutive PsA patients and the next
536 patients seen with inflammatory arthritis as the control
(72% RA). PsA cases and controls were classified by existing
criteria for respective accuracy, and new classification items
were constructed. The CASPAR criteria (Table 1) include
characteristic dermatologic, clinical, and radiographic features

and have demonstrated high sensitivity (91.4%) and specificity
(98.7%) (16). The CASPAR criteria enable classification of PsA
in patients without psoriasis, but other associated features.
The CASPAR criteria have subsequently been validated in
early PsA cohorts (20, 21), retrospective cohorts (22), primary
health care settings (20), and other ethnicities (23). Currently,
the CASPAR criteria have become the most widely used
criteria for recruitment in both RCTs and LOS (14). The only
concern about the CASPAR criteria is the initial qualification
criterion (stem question): inflammatory musculoskeletal (MSK)

FIGURE 1 | Work stream for update of core domain set for PsA 2016. Work processes in circles. *Indicates involvement of patients.
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Measurement of Meaningful Outcomes in
PsA

disease including either spinal, peripheral joint or entheseal
manifestations. It may be difficult for practitioners other
than rheumatologists, such as dermatologists, to differentiate
inflammatory arthritis from other non-specific aches and pains
in tendons and joints. GRAPPA is currently working on methods
to better define inflammatory MSK disease (24).
More recently, the Assessment of SpondyloArthritis
International Society (ASAS) developed peripheral (pSpA)
and axial spondyloarthritis (AxSpA) criteria, where PsA
could be classified under both pSpA or AxSpA (25). In a
cohort of early arthritis, the pSpA criteria were found to have
lower sensitivity for early PsA compared with the CASPAR
criteria (26). However, patients with dactylitis or enthesitis
or predominantly AxSpA were excluded from this validation
cohort which may have limited the performance of these
criteria. Moreover, all validation studies for spondyloarthritis
classification criteria thus far have been based on a case control
design; introducing possible bias by over-estimating sensitivity
and specificity of the criteria (27). After all, constructing criteria
for SpA may be challenging because it is inclusive of many
heterogeneous disorders. It may be more rational to separate PsA
and AxSpA into different more homogeneous phenotypic
entities, thus facilitating both instrument development
and measurement of clinical outcomes in the long term
(28, 29).

Advances in the development of biologic therapies have offered
hope for better treatment for patients with PsA since early
2000s. However, meta-analyses of results from RCTs have been
hampered by the lack of homogeneity in outcome measures
in PsA. Just a decade ago, most of the instruments for PsA
were borrowed from RA RCTs (30, 31). Instruments that
function well in other forms of arthritis may not necessarily
measure what it is intended to be measured in PsA. For
instance, the reduced 28-joint count in RA that focuses on
hand joints grossly underestimates disease burden in PsA as
the feet are most commonly affected in PsA (32). Unlike
measurement of blood sugar levels in diabetes mellitus, the
concept of disease control in PsA is a construct that is more
difficult to define. It is generally accepted that amelioration
of inflammation with effective treatment reduces symptoms,
prevents damage accumulation and reduces adverse health
outcomes from comorbidities. Traditional serum inflammatory
biomarkers such as erythrocyte sedimentation rate and Creactive protein are well-known to be elevated in <30% of
patients with active disease (33), and therefore may not reflect
underlying disease activity. A challenge to quantify disease
activity and impact of PsA are the diverse clinical manifestations
that span across peripheral and axial joint arthritis, enthesitis,
dactylitis, psoriatic skin, and nail lesions. Moreover, while disease
activity and disease impact in PsA are different constructs
they are not totally independent of each other. People affected
by PsA may have different views compared with clinicians
on which disease manifestations and impact are important to
them (34).
Over the past decade, many disease specific instruments
for the assessment of various domains have been developed
and validated for use in RCTs (35). However, the lack
of standardization of domains and instruments in RCTs
is problematic. Heterogeneity in domain measurement with
multiple instruments per domain in PsA RCTs (36, 37) can hinder
the comparability of efficacy assessments across interventions.
Established in 1992, the OMERACT international consensus
effort has been working to improve outcome measures
for use in RCTs and LOS in rheumatology, building on
“Truth,” “Discrimination,” and “Feasibility” (38). “Truth” means
measuring what is intended to be measured in a relevant and
unbiased manner. It captures issues of face, content, construct,
and criterion validity. “Discrimination” means whether an
instrument discriminate between situations of interest, such
as disease states at different time points to measure change
and also captures issues of reliability and sensitivity to change.
“Feasibility” assesses whether the instrument can be easily
applied, given constraints of time, money, and interpretability.
OMERACT has recently updated and outlined a conceptual
framework for core set development (Filter 2.1) that encompasses
both patient-centered and intervention specific information (39).
This framework specifies four key components termed “Area” of
a health condition to ensure comprehensive coverage: three Areas
that describe the “Impact of Health Conditions,” specifically

FIGURE 2 | Updated 2016 psoriatic arthritis (PsA) core domain set.
Reproduced with permission from Orbai et al. (45). Musculoskeletal (MSK)
disease activity includes peripheral joints, enthesitis, dactylitis, and spine
symptoms; skin activity includes skin and nails; patient global is defined as
patient-reported disease-related health status. The inner circle (core) includes
domains that should be measured in all randomized controlled trials and
longitudinal observational studies. The middle circle includes domains that are
important but may not be feasible to assess in all RCTs and LOS. The outer
circle (or research agenda) includes domains that may be important but need
further study.
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TABLE 2 | Examples of candidate instruments for the PsA core instrument set.

TABLE 2 | Continued

2016 PsA Core
outcome set
(inner circle)

2016 PsA Core
outcome set
(inner circle)

Candidate outcome measurement instruments
prioritized for apprasial using OMERACT filter 2.1

MSK DISEASE ACTIVITY

HRQoL/LIFE IMPACT

MSK disease
activity/Arthritis

66/68 swollen/tender joint count*†

MSK disease
activity/Dactylitis

Leeds Dactylitis Index (LDI) (0–60)
LDI basic, no grading (score range 0–20)

MSK disease
activity/Enthesitis

Leeds Enthesitis Index (LEI)—(6 sites)
Spondyloarthritis Research Consortium of Canada Index
(SPARCC)—(16 sites)
Maastricht Ankylosing Spondylitis Enthesis Score
(MASES)—(13 sites)
Impact Index—(4 sites)

MSK disease
activity/Spine

Candidate outcome measurement instruments
prioritized for apprasial using OMERACT filter 2.1

HRQoL

PROMs
Disease specific: PsAID*†
Generic: SF36 PCS/MCS and 8 domains
Generic: PROMIS Profiles
Generic to Dermatology (not specific to psoriasis):
Dernatology Life Quality Index (DLQI)

FATIGUE
PROMs
Functional Assessment of Chronic Illness Therapy
(FACIT)-Fatigue
SF-36 Vitality domain
PROMIS Fatigue
VAS Fatigue
NRS Fatigue
Fatigue Severity Score (FSS)
Fatigue Assessment Scale (FAS)
Bristol RA Fatigue (BRAF) (3 NRS scales)
Multidimensional Assessment of Fatigue (MAF)

Research agenda

SKIN DISEASE ACTIVITY
Skin disease
activity/Skin

Skin disease
activity/Nail

Psoriasis Area and Severity Index (PASI)
Psoriasis Body Surface Area (BSA)
Target psoriatic skin lesion score (0–12)
Physician global assessment of psoriasis (PSGA/PGA) (0–5)
Mean Body Surface Area involved
PROMs
Psoriasis Symptom Inventory (PSI)
Psoriasis Symptom Diary (PSD)
Worst Itch VAS
Patient Assessment Skin Status (Likert)

SYSTEMIC INFLAMMATION
Laboratory assays from a patient’s blood/serum
C-Reactive Protein (CRP)*
Erytrocyte Sedimentation Rate (ESR)*
†

*Completed evaluation; endorsed/ provisionally endorsed; PROM, patient reported
outcome measures; VAS, visual analogue scale; NRS, numeric rating scale; MSK,
musculoskeletal; PROMIS, Patient-Reported Outcomes Measurement Information
System; SF-36, Medical Outcome Short Form 36; PCS, Physical Summary Scale of
SF-36; MCS, Mental Summary Scale of SF-36; PsAID, Psoriatic Arthritis Impact of
Disease.

Physician performed by inspection of (looking at) the
patient’s nails
Nail Psoriasis Severity Index (NAPSI) (0–80 finger nails only; or
0–160 finger and toe nails)
Modified Nail Psoriasis Severity Index (mNAPSI) (0–130)
Target NAPSI score (0–13)
VAS Nail Psoriasis

Death, Life Impact, and Resource Use; and the fourth Area that
describes Pathophysiological manifestations. The OMERACT
filter 2.1 has also attempted to distinguish two major components
in outcome research, namely, determining “what to measure”
before deciding on “how to measure” them. Within this concept,
the development of “Core Domain Sets” followed by “Core
Measurement Sets” with defined instruments was set forth. Each
instrument in the final core measurement set must prove to be
truthful, discriminative, and feasible (39).

PAIN
PROMs
0–100 VAS Pain (1 week recall)
0–100 VAS Pain (recall not specified)
0–10 NRS Pain (1 week recall)
PROMIS Pain Intensity
PROMIS Pain Interference
PATIENT GLOBAL
PROMs:
Patient global due to psoriasis
0–10 NRS (1 week recall)
0–100 VAS (1 week recall)
Patient global due to arthritis
0–10 NRS (1 week recall)
0–10 NRS (1 day recall)
0–100 VAS (1 week recall)
Patient global due to skin disease
0–10 NRS (1 week recall)
0–100 VAS (1 week recall)
0–100 VAS (recall not specified)

Development of Core Domain Set for PsA
Working with OMERACT, GRAPPA researchers defined the
first core domain set for use in both RCTs and LOS in 2006
(40). A need to update the core domain set was identified
as our understanding of PsA advanced over the years, and
to include important patient input. The concept of involving
patients as research partners (PRPs) was recognized as an
essential and valuable component in the process (39, 41). Without
incorporating the experience of disease through involvement of
patients it is not possible to fulfill the “truth” or “feasibility”
element of the OMERACT filter. The role of PRPs has evolved
from informing disease impact via participation in qualitative
studies to much broader participation in study design and

PHYSICAL FUNCTION
Health Assessment Questionnaire Disability Index (HAQ-DI)
SF-36 Physical Function domain
PROMIS Physical Function
(Continued)
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4) How responsive the instrument is to change of status of
disease (Discrimination).

conduct (42). OMERACT has continued to publish updated
guidelines on core set development. Therefore, it was deemed
important to update the PsA core domain set incorporating
patients’ perspectives in multiple steps, and in accordance with
the OMERACT filter 2.1 (43).
GRAPPA has assembled an international collaborative effort
to update the PsA core domain set since 2014. Patients have
been involved in all steps of development (conducting focus
groups and analyzing data, including PRPs who functioned in
the high-level conduct of the research; Figure 1). The detailed
processes of core set development have been published elsewhere
(44, 45). In brief, it started with identification of possible domains
from a comprehensive literature search, as well as the previously
identified domains from 2006 (37). Patients’ perspectives on
how PsA impacts their lives were actively sought through
an international focus group involving 130 patients across 7
countries representing 5 continents; together with a UK multicentered focus group study. Two independent Delphi surveys
with health care providers and patients were then conducted
to rate the importance of each domain. The selection of each
domain was discussed in face-to-face nominal groups conducted
with 12 clinicians, 12 patients, and 2 non-voting fellows in
March 2016 in New Jersey, USA. Thorough exchange of ideas
and perspectives between clinicians and patients were achieved,
revealing differences but aiding resolution and consensus. A
second Delphi survey round followed. Candidate domains were
presented and endorsed at OMERACT 2016.
The final PsA core domain set includes three parts: an
inner circle (should be measured in all RCTs and LOS),
a middle circle (important to be measured at some point
in the drug development program, but not mandatory),
and the outer circle that represents the research agenda
(Figure 2). The inner circle includes MSK disease activity
(peripheral joints, enthesitis, dactylitis, and spine involvement),
skin disease activity (skin and nails involvement), pain,
patient’s global assessment, physical function, healthrelated quality of life, fatigue, and systemic inflammation
biomarkers (Figure 2). This core domain set, developed
with extensive patient involvement and representation of
stakeholders from 5 continents, achieved general consensus
and provides guidance as to what to measure in PsA RCTs and
LOS.

The work stream started with evaluation of the existing evidence
on PsA instrument properties through systemic literature reviews
and data analyses from RCTs, followed by Delphi processes
with stakeholders (including patients, clinicians, methodologists,
and payers), and working group meetings and discussion
(46). Thus far, evaluation of evidence on existing patient
reported outcomes (47), MSK disease activities and systemic
inflammation (48) have been completed. The 66/68 joint count
and Psoriatic arthritis impact of disease (PsAID12) that measure
peripheral MSK disease activity and health-related quality of
life or impact of disease, respectively, have been thoroughly
evaluated by the GRAPPA/OMERACT working group. At the
OMERACT 2018 conference in Terrigal Australia, the 66/68
joint count was endorsed and PsAID received provisional
endorsement.
The GRAPPA core set working group will continue its work
on proper evaluation of measurement properties for existing and
new instruments for other domains and will seek consensus to
standardize the outcome measurement set for the other domains,
including MSK manifestations such as dactylitis and enthesitis;
and physical function will be taken forward for appraisal using
the OMERACT filter 2.1 (Table 2). The aim is to create a full core
instrument set to complete the core domain set for PsA in the
coming years.

CONCLUSION
With new therapeutic options for PsA and a growing number of
RCTs and LOS in PsA, it is important to understand how best
to measure disease activity and its impact. GRAPPA/OMERACT
have been playing a leading role in informing how best to
assess PsA. The CASPAR criteria remain the cornerstone for
classifying PsA patients for enrolment in RCTs and LOS. The
PsA core domain set has been updated to guide the measurement
of outcomes that are relevant to both clinicians and patients.
It will be important to continue to standardize outcome
measures for RCTs and LOS in PsA. Using OMERACT’s updated
methodology to generate the best evidence will be essential
establishing consensus among various stakeholders. This
standardized outcome measurement set will provide a standard
for subsequent RCTs/LOS in PsA, as well as to assist clinicians
and patients in understanding the best evidence for a particular
treatment.

Development of Core Outcome
Measurement Set for PsA
Following development of the core domain set, the GRAPPAOMERACT PsA core set working group is leading the work to
standardize the core outcome measurement set according to the
OMERACT filter methodology (46). This methodology evaluates
each instrument with four pillars of OMERACT:
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